Sources :
(1) Fernstrom, J. D. Role of Precursor Availability in Control of Monoamine Biosynthesis in Brain. Physiol. Rev. 1983, 63 (2), 484–546. https://doi.org/10.1152/physrev.1983.63.2.484.
(2) Ruhé, H. G.; Mason, N. S.; Schene, A. H. Mood Is Indirectly Related to Serotonin, Norepinephrine and Dopamine Levels in Humans: A Meta-Analysis of Monoamine Depletion Studies. Mol. Psychiatry 2007, 12 (4), 331–359. https://doi.org/10.1038/sj.mp.4001949.
(3) Szczepanik, M. Melatonin and Its Influence on Immune System. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 2007, 58 Suppl 6, 115–124.
(4) Martin, S. L.; Power, A.; Boyle, Y.; Anderson, I. M.; Silverdale, M. A.; Jones, A. K. P. 5-HT Modulation of Pain Perception in Humans. Psychopharmacology (Berl.) 2017, 234 (19), 2929–2939. https://doi.org/10.1007/s00213-017-4686-6.
(5) Oldendorf, W. H.; Szabo, J. Amino Acid Assignment to One of Three Blood-Brain Barrier Amino Acid Carriers. Am. J. Physiol. 1976, 230 (1), 94–98. https://doi.org/10.1152/ajplegacy.1976.230.1.94.
(6) Kruse, T.; Reiber, H.; Neuhoff, V. Amino Acid Transport across the Human Blood-CSF Barrier. An Evaluation Graph for Amino Acid Concentrations in Cerebrospinal Fluid. J. Neurol. Sci. 1985, 70 (2), 129–138. https://doi.org/10.1016/0022-510x(85)90082-6.
(7) Gardiner, R. M. Transport of Amino Acids across the Blood-Brain Barrier: Implications for Treatment of Maternal Phenylketonuria. J. Inherit. Metab. Dis. 1990, 13 (4), 627–633. https://doi.org/10.1007/BF01799517.
(8) Lucini, V.; Lucca, A.; Catalano, M.; Smeraldi, E. Predictive Value of Tryptophan/Large Neutral Amino Acids Ratio to Antidepressant Response. J. Affect. Disord. 1996, 36 (3–4), 129–133. https://doi.org/10.1016/0165-0327(95)00071-2.
(9) Matalon, R.; Surendran, S.; Matalon, K. M.; Tyring, S.; Quast, M.; Jinga, W.; Ezell, E.; Szucs, S. Future Role of Large Neutral Amino Acids in Transport of Phenylalanine into the Brain. Pediatrics 2003, 112 (6 Pt 2), 1570–1574.
(10) Dudek, K. A.; Dion-Albert, L.; Lebel, M.; LeClair, K.; Labrecque, S.; Tuck, E.; Ferrer Perez, C.; Golden, S. A.; Tamminga, C.; Turecki, G.; Mechawar, N.; Russo, S. J.; Menard, C. Molecular Adaptations of the Blood-Brain Barrier Promote Stress Resilience vs. Depression. Proc. Natl. Acad. Sci. U. S. A. 2020, 117 (6), 3326–3336. https://doi.org/10.1073/pnas.1914655117.
(11) Fernstrom, J. D.; Wurtman, R. J.; Hammarstrom-Wiklund, B.; Rand, W. M.; Munro, H. N.; Davidson, C. S. Diurnal Variations in Plasma Concentrations of Tryptophan, Tryosine, and Other Neutral Amino Acids: Effect of Dietary Protein Intake. Am. J. Clin. Nutr. 1979, 32 (9), 1912–1922. https://doi.org/10.1093/ajcn/32.9.1912.
(12) Lieberman, H. R.; Caballero, B.; Finer, N. The Composition of Lunch Determines Afternoon Plasma Tryptophan Ratios in Humans. J. Neural Transm. 1986, 65 (3–4), 211–217. https://doi.org/10.1007/BF01249083.
(13) Caballero, B.; Finer, N.; Wurtman, R. J. Plasma Amino Acids and Insulin Levels in Obesity: Response to Carbohydrate Intake and Tryptophan Supplements. Metabolism. 1988, 37 (7), 672–676. https://doi.org/10.1016/0026-0495(88)90089-3.
(14) Lyons, P. M.; Truswell, A. S. Serotonin Precursor Influenced by Type of Carbohydrate Meal in Healthy Adults. Am. J. Clin. Nutr. 1988, 47 (3), 433–439. https://doi.org/10.1093/ajcn/47.3.433.
(15) Sainio, E. L.; Pulkki, K.; Young, S. N. L-Tryptophan: Biochemical, Nutritional and Pharmacological Aspects. Amino Acids 1996, 10 (1), 21–47. https://doi.org/10.1007/BF00806091.
(16) Wurtman, R. J.; Wurtman, J. J.; Regan, M. M.; McDermott, J. M.; Tsay, R. H.; Breu, J. J. Effects of Normal Meals Rich in Carbohydrates or Proteins on Plasma Tryptophan and Tyrosine Ratios. Am. J. Clin. Nutr. 2003, 77 (1), 128–132. https://doi.org/10.1093/ajcn/77.1.128.
(17) Kaye, W. H.; Frank, G. K.; Meltzer, C. C.; Price, J. C.; McConaha, C. W.; Crossan, P. J.; Klump, K. L.; Rhodes, L. Altered Serotonin 2A Receptor Activity in Women Who Have Recovered from Bulimia Nervosa. Am. J. Psychiatry 2001, 158 (7), 1152–1155. https://doi.org/10.1176/appi.ajp.158.7.1152.
(18) Steiger, H. Eating Disorders and the Serotonin Connection: State, Trait and Developmental Effects. J. Psychiatry Neurosci. 2004, 29 (1), 20–29.
(19) Steiger, H.; Gauvin, L.; Joober, R.; Israel, M.; Ng Ying Kin, N. M. K.; Bruce, K. R.; Richardson, J.; Young, S. N.; Hakim, J. Intrafamilial Correspondences on Platelet [3H-]Paroxetine-Binding Indices in Bulimic Probands and Their Unaffected First-Degree Relatives. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2006, 31 (8), 1785–1792. https://doi.org/10.1038/sj.npp.1301011.
(20) Bruce, K. R.; Steiger, H.; Young, S. N.; Kin, N. M. K. N. Y.; Israël, M.; Lévesque, M. Impact of Acute Tryptophan Depletion on Mood and Eating-Related Urges in Bulimic and Nonbulimic Women. J. Psychiatry Neurosci. JPN 2009, 34 (5), 376–382.
(21) Sjögren, M.; Nielsen, A. S. M.; Hasselbalch, K. C.; Wøllo, M.; Hansen, J. S. A Systematic Review of Blood-Based Serotonergic Biomarkers in Bulimia Nervosa. Psychiatry Res. 2019, 279, 155–171. https://doi.org/10.1016/j.psychres.2018.12.167.
(22) Bruinsma, K.; Taren, D. L. Chocolate: Food or Drug? J. Am. Diet. Assoc. 1999, 99 (10), 1249–1256. https://doi.org/10.1016/S0002-8223(99)00307-7.
(23) Sokolov, A. N.; Pavlova, M. A.; Klosterhalfen, S.; Enck, P. Chocolate and the Brain: Neurobiological Impact of Cocoa Flavanols on Cognition and Behavior. Neurosci. Biobehav. Rev. 2013, 37 (10 Pt 2), 2445–2453. https://doi.org/10.1016/j.neubiorev.2013.06.013.
(24) Scholey, A.; Owen, L. Effects of Chocolate on Cognitive Function and Mood: A Systematic Review. Nutr. Rev. 2013, 71 (10), 665–681. https://doi.org/10.1111/nure.12065.
(25) Meier, B. P.; Noll, S. W.; Molokwu, O. J. The Sweet Life: The Effect of Mindful Chocolate Consumption on Mood. Appetite 2017, 108, 21–27. https://doi.org/10.1016/j.appet.2016.09.018.
(26) Takikawa, O. Biochemical and Medical Aspects of the Indoleamine 2,3-Dioxygenase-Initiated L-Tryptophan Metabolism. Biochem. Biophys. Res. Commun. 2005, 338 (1), 12–19. https://doi.org/10.1016/j.bbrc.2005.09.032.
(27) Ball, H. J.; Yuasa, H. J.; Austin, C. J. D.; Weiser, S.; Hunt, N. H. Indoleamine 2,3-Dioxygenase-2; a New Enzyme in the Kynurenine Pathway. Int. J. Biochem. Cell Biol. 2009, 41 (3), 467–471. https://doi.org/10.1016/j.biocel.2008.01.005.
(28) Ruddick, J. P.; Evans, A. K.; Nutt, D. J.; Lightman, S. L.; Rook, G. A. W.; Lowry, C. A. Tryptophan Metabolism in the Central Nervous System: Medical Implications. Expert Rev. Mol. Med. 2006, 8 (20), 1–27. https://doi.org/10.1017/S1462399406000068.
(29) Clarke, G.; Fitzgerald, P.; Cryan, J. F.; Cassidy, E. M.; Quigley, E. M.; Dinan, T. G. Tryptophan Degradation in Irritable Bowel Syndrome: Evidence of Indoleamine 2,3-Dioxygenase Activation in a Male Cohort. BMC Gastroenterol. 2009, 9, 6. https://doi.org/10.1186/1471-230X-9-6.
(30) Schwarcz, R.; Bruno, J. P.; Muchowski, P. J.; Wu, H.-Q. Kynurenines in the Mammalian Brain: When Physiology Meets Pathology. Nat. Rev. Neurosci. 2012, 13 (7), 465–477. https://doi.org/10.1038/nrn3257.
(31) O’Mahony, S. M.; Clarke, G.; Borre, Y. E.; Dinan, T. G.; Cryan, J. F. Serotonin, Tryptophan Metabolism and the Brain-Gut-Microbiome Axis. Behav. Brain Res. 2015, 277, 32–48. https://doi.org/10.1016/j.bbr.2014.07.027.
(32) Baban, B.; Chandler, P. R.; Sharma, M. D.; Pihkala, J.; Koni, P. A.; Munn, D. H.; Mellor, A. L. IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells. J. Immunol. 2009, 183 (4), 2475–2483. https://doi.org/10.4049/jimmunol.0900986.
(33) Kałużna-Czaplińska, J.; Gątarek, P.; Chirumbolo, S.; Chartrand, M. S.; Bjørklund, G. How Important Is Tryptophan in Human Health? Crit. Rev. Food Sci. Nutr. 2019, 59 (1), 72–88. https://doi.org/10.1080/10408398.2017.1357534.
(34) Savitz, J. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders. Curr. Top. Behav. Neurosci. 2017, 31, 249–267. https://doi.org/10.1007/7854_2016_12.
(35) Bryleva, E. Y.; Brundin, L. Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism. Curr. Top. Behav. Neurosci. 2017, 31, 269–284. https://doi.org/10.1007/7854_2016_5.
(36) Serafini, G.; Adavastro, G.; Canepa, G.; Capobianco, L.; Conigliaro, C.; Pittaluga, F.; Murri, M. B.; Valchera, A.; De Berardis, D.; Pompili, M.; Lindqvist, D.; Brundin, L.; Amore, M. Abnormalities in Kynurenine Pathway Metabolism in Treatment-Resistant Depression and Suicidality: A Systematic Review. CNS Neurol. Disord. Drug Targets 2017, 16 (4), 440–453. https://doi.org/10.2174/1871527316666170413110605.
(37) Clarke, G.; McKernan, D. P.; Gaszner, G.; Quigley, E. M.; Cryan, J. F.; Dinan, T. G. A Distinct Profile of Tryptophan Metabolism along the Kynurenine Pathway Downstream of Toll-Like Receptor Activation in Irritable Bowel Syndrome. Front. Pharmacol. 2012, 3, 90. https://doi.org/10.3389/fphar.2012.00090.
(38) Gulaj, E.; Pawlak, K.; Bien, B.; Pawlak, D. Kynurenine and Its Metabolites in Alzheimer’s Disease Patients. Adv. Med. Sci. 2010, 55 (2), 204–211. https://doi.org/10.2478/v10039-010-0023-6.
(39) Tan, L.; Yu, J.-T.; Tan, L. The Kynurenine Pathway in Neurodegenerative Diseases: Mechanistic and Therapeutic Considerations. J. Neurol. Sci. 2012, 323 (1–2), 1–8. https://doi.org/10.1016/j.jns.2012.08.005.
(40) Meier, T. B.; Drevets, W. C.; Wurfel, B. E.; Ford, B. N.; Morris, H. M.; Victor, T. A.; Bodurka, J.; Teague, T. K.; Dantzer, R.; Savitz, J. Relationship between Neurotoxic Kynurenine Metabolites and Reductions in Right Medial Prefrontal Cortical Thickness in Major Depressive Disorder. Brain. Behav. Immun. 2016, 53, 39–48. https://doi.org/10.1016/j.bbi.2015.11.003.
(41) Birner, A.; Platzer, M.; Bengesser, S. A.; Dalkner, N.; Fellendorf, F. T.; Queissner, R.; Pilz, R.; Rauch, P.; Maget, A.; Hamm, C.; Herzog-Eberhard, S.; Mangge, H.; Fuchs, D.; Moll, N.; Zelzer, S.; Schütze, G.; Schwarz, M.; Reininghaus, B.; Kapfhammer, H.-P.; Reininghaus, E. Z. Increased Breakdown of Kynurenine towards Its Neurotoxic Branch in Bipolar Disorder. PloS One 2017, 12 (2), e0172699. https://doi.org/10.1371/journal.pone.0172699.
(42) Sas, K.; Szabó, E.; Vécsei, L. Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection. Mol. Basel Switz. 2018, 23 (1). https://doi.org/10.3390/molecules23010191.
(43) Mangge, H.; Stelzer, I.; Reininghaus, E. Z.; Weghuber, D.; Postolache, T. T.; Fuchs, D. Disturbed Tryptophan Metabolism in Cardiovascular Disease. Curr. Med. Chem. 2014, 21 (17), 1931–1937. https://doi.org/10.2174/0929867321666140304105526.
(44) Song, P.; Ramprasath, T.; Wang, H.; Zou, M.-H. Abnormal Kynurenine Pathway of Tryptophan Catabolism in Cardiovascular Diseases. Cell. Mol. Life Sci. CMLS 2017, 74 (16), 2899–2916. https://doi.org/10.1007/s00018-017-2504-2.
(45) Oxenkrug, G. Insulin Resistance and Dysregulation of Tryptophan-Kynurenine and Kynurenine-Nicotinamide Adenine Dinucleotide Metabolic Pathways. Mol. Neurobiol. 2013, 48 (2), 294–301. https://doi.org/10.1007/s12035-013-8497-4.
(46) Matsuoka, K.; Kato, K.; Takao, T.; Ogawa, M.; Ishii, Y.; Shimizu, F.; Masuda, J.; Takada, A. Concentrations of Various Tryptophan Metabolites Are Higher in Patients with Diabetes Mellitus than in Healthy Aged Male Adults. Diabetol. Int. 2016, 8 (1), 69–75. https://doi.org/10.1007/s13340-016-0282-y.
(47) Mangge, H.; Summers, K. L.; Meinitzer, A.; Zelzer, S.; Almer, G.; Prassl, R.; Schnedl, W. J.; Reininghaus, E.; Paulmichl, K.; Weghuber, D.; Fuchs, D. Obesity-Related Dysregulation of the Tryptophan-Kynurenine Metabolism: Role of Age and Parameters of the Metabolic Syndrome. Obes. Silver Spring Md 2014, 22 (1), 195–201. https://doi.org/10.1002/oby.20491.
(48) Mallmann, N. H.; Lima, E. S.; Lalwani, P. Dysregulation of Tryptophan Catabolism in Metabolic Syndrome. Metab. Syndr. Relat. Disord. 2018, 16 (3), 135–142. https://doi.org/10.1089/met.2017.0097.
(49) Pedersen, E. R.; Svingen, G. F. T.; Schartum-Hansen, H.; Ueland, P. M.; Ebbing, M.; Nordrehaug, J. E.; Igland, J.; Seifert, R.; Nilsen, R. M.; Nygård, O. Urinary Excretion of Kynurenine and Tryptophan, Cardiovascular Events, and Mortality after Elective Coronary Angiography. Eur. Heart J. 2013, 34 (34), 2689–2696. https://doi.org/10.1093/eurheartj/eht264.
(50) Sulo, G.; Vollset, S. E.; Nygård, O.; Midttun, Ø.; Ueland, P. M.; Eussen, S. J. P. M.; Pedersen, E. R.; Tell, G. S. Neopterin and Kynurenine-Tryptophan Ratio as Predictors of Coronary Events in Older Adults, the Hordaland Health Study. Int. J. Cardiol. 2013, 168 (2), 1435–1440. https://doi.org/10.1016/j.ijcard.2012.12.090.
(51) Rebnord, E. W.; Strand, E.; Midttun, Ø.; Svingen, G. F. T.; Christensen, M. H. E.; Ueland, P. M.; Mellgren, G.; Njølstad, P. R.; Tell, G. S.; Nygård, O. K.; Pedersen, E. R. The Kynurenine:Tryptophan Ratio as a Predictor of Incident Type 2 Diabetes Mellitus in Individuals with Coronary Artery Disease. Diabetologia 2017, 60 (9), 1712–1721. https://doi.org/10.1007/s00125-017-4329-9.
(52) Sorgdrager, F. J. H.; Naudé, P. J. W.; Kema, I. P.; Nollen, E. A.; Deyn, P. P. D. Tryptophan Metabolism in Inflammaging: From Biomarker to Therapeutic Target. Front. Immunol. 2019, 10, 2565. https://doi.org/10.3389/fimmu.2019.02565.
(53) Lyte, M. Probiotics Function Mechanistically as Delivery Vehicles for Neuroactive Compounds: Microbial Endocrinology in the Design and Use of Probiotics. BioEssays News Rev. Mol. Cell. Dev. Biol. 2011, 33 (8), 574–581. https://doi.org/10.1002/bies.201100024.
(54) Barrett, E.; Ross, R. P.; O’Toole, P. W.; Fitzgerald, G. F.; Stanton, C. γ-Aminobutyric Acid Production by Culturable Bacteria from the Human Intestine. J. Appl. Microbiol. 2012, 113 (2), 411–417. https://doi.org/10.1111/j.1365-2672.2012.05344.x.
(55) Strandwitz, P.; Kim, K. H.; Terekhova, D.; Liu, J. K.; Sharma, A.; Levering, J.; McDonald, D.; Dietrich, D.; Ramadhar, T. R.; Lekbua, A.; Mroue, N.; Liston, C.; Stewart, E. J.; Dubin, M. J.; Zengler, K.; Knight, R.; Gilbert, J. A.; Clardy, J.; Lewis, K. GABA-Modulating Bacteria of the Human Gut Microbiota. Nat. Microbiol. 2019, 4 (3), 396–403. https://doi.org/10.1038/s41564-018-0307-3.
(56) Dodd, D.; Spitzer, M. H.; Van Treuren, W.; Merrill, B. D.; Hryckowian, A. J.; Higginbottom, S. K.; Le, A.; Cowan, T. M.; Nolan, G. P.; Fischbach, M. A.; Sonnenburg, J. L. A Gut Bacterial Pathway Metabolizes Aromatic Amino Acids into Nine Circulating Metabolites. Nature 2017, 551 (7682), 648–652. https://doi.org/10.1038/nature24661.
(57) Alexeev, E. E.; Lanis, J. M.; Kao, D. J.; Campbell, E. L.; Kelly, C. J.; Battista, K. D.; Gerich, M. E.; Jenkins, B. R.; Walk, S. T.; Kominsky, D. J.; Colgan, S. P. Microbiota-Derived Indole Metabolites Promote Human and Murine Intestinal Homeostasis through Regulation of Interleukin-10 Receptor. Am. J. Pathol. 2018, 188 (5), 1183–1194. https://doi.org/10.1016/j.ajpath.2018.01.011.
(58) Lamas, B.; Richard, M. L.; Leducq, V.; Pham, H.-P.; Michel, M.-L.; Da Costa, G.; Bridonneau, C.; Jegou, S.; Hoffmann, T. W.; Natividad, J. M.; Brot, L.; Taleb, S.; Couturier-Maillard, A.; Nion-Larmurier, I.; Merabtene, F.; Seksik, P.; Bourrier, A.; Cosnes, J.; Ryffel, B.; Beaugerie, L.; Launay, J.-M.; Langella, P.; Xavier, R. J.; Sokol, H. CARD9 Impacts Colitis by Altering Gut Microbiota Metabolism of Tryptophan into Aryl Hydrocarbon Receptor Ligands. Nat. Med. 2016, 22 (6), 598–605. https://doi.org/10.1038/nm.4102.
(59) de Mello, V. D.; Paananen, J.; Lindström, J.; Lankinen, M. A.; Shi, L.; Kuusisto, J.; Pihlajamäki, J.; Auriola, S.; Lehtonen, M.; Rolandsson, O.; Bergdahl, I. A.; Nordin, E.; Ilanne-Parikka, P.; Keinänen-Kiukaanniemi, S.; Landberg, R.; Eriksson, J. G.; Tuomilehto, J.; Hanhineva, K.; Uusitupa, M. Indolepropionic Acid and Novel Lipid Metabolites Are Associated with a Lower Risk of Type 2 Diabetes in the Finnish Diabetes Prevention Study. Sci. Rep. 2017, 7, 46337. https://doi.org/10.1038/srep46337.
(60) Galligan, J. J. Beneficial Actions of Microbiota-Derived Tryptophan Metabolites. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 2018, 30 (2). https://doi.org/10.1111/nmo.13283.
(61) Agus, A.; Planchais, J.; Sokol, H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe 2018, 23 (6), 716–724. https://doi.org/10.1016/j.chom.2018.05.003.
(62) Krishnan, S.; Ding, Y.; Saedi, N.; Choi, M.; Sridharan, G. V.; Sherr, D. H.; Yarmush, M. L.; Alaniz, R. C.; Jayaraman, A.; Lee, K. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep. 2018, 23 (4), 1099–1111. https://doi.org/10.1016/j.celrep.2018.03.109.
(63) Nikolaus, S.; Schulte, B.; Al-Massad, N.; Thieme, F.; Schulte, D. M.; Bethge, J.; Rehman, A.; Tran, F.; Aden, K.; Häsler, R.; Moll, N.; Schütze, G.; Schwarz, M. J.; Waetzig, G. H.; Rosenstiel, P.; Krawczak, M.; Szymczak, S.; Schreiber, S. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases. Gastroenterology 2017, 153 (6), 1504-1516.e2. https://doi.org/10.1053/j.gastro.2017.08.028.
(64) Kraneveld, A. D.; Szklany, K.; de Theije, C. G. M.; Garssen, J. Gut-to-Brain Axis in Autism Spectrum Disorders: Central Role for the Microbiome. Int. Rev. Neurobiol. 2016, 131, 263–287. https://doi.org/10.1016/bs.irn.2016.09.001.
(65) Clarke, G.; Grenham, S.; Scully, P.; Fitzgerald, P.; Moloney, R. D.; Shanahan, F.; Dinan, T. G.; Cryan, J. F. The Microbiome-Gut-Brain Axis during Early Life Regulates the Hippocampal Serotonergic System in a Sex-Dependent Manner. Mol. Psychiatry 2013, 18 (6), 666–673. https://doi.org/10.1038/mp.2012.77.
(66) Distrutti, E.; O’Reilly, J.-A.; McDonald, C.; Cipriani, S.; Renga, B.; Lynch, M. A.; Fiorucci, S. Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP. PLoS ONE 2014, 9 (9). https://doi.org/10.1371/journal.pone.0106503.
(67) Akbari, E.; Asemi, Z.; Daneshvar Kakhaki, R.; Bahmani, F.; Kouchaki, E.; Tamtaji, O. R.; Hamidi, G. A.; Salami, M. Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer’s Disease: A Randomized, Double-Blind and Controlled Trial. Front. Aging Neurosci. 2016, 8, 256. https://doi.org/10.3389/fnagi.2016.00256.
(68) Mancuso, C.; Santangelo, R. Alzheimer’s Disease and Gut Microbiota Modifications: The Long Way between Preclinical Studies and Clinical Evidence. Pharmacol. Res. 2018, 129, 329–336. https://doi.org/10.1016/j.phrs.2017.12.009.
(69) Zemke, D.; Majid, A. The Potential of Minocycline for Neuroprotection in Human Neurologic Disease. Clin. Neuropharmacol. 2004, 27 (6), 293–298. https://doi.org/10.1097/01.wnf.0000150867.98887.3e.
(70) O’Connor, J. C.; Lawson, M. A.; André, C.; Moreau, M.; Lestage, J.; Castanon, N.; Kelley, K. W.; Dantzer, R. Lipopolysaccharide-Induced Depressive-like Behavior Is Mediated by Indoleamine 2,3-Dioxygenase Activation in Mice. Mol. Psychiatry 2009, 14 (5), 511–522. https://doi.org/10.1038/sj.mp.4002148.
(71) Mello, B. S. F.; Monte, A. S.; McIntyre, R. S.; Soczynska, J. K.; Custódio, C. S.; Cordeiro, R. C.; Chaves, J. H.; Vasconcelos, S. M. M.; Nobre, H. V.; Florenço de Sousa, F. C.; Hyphantis, T. N.; Carvalho, A. F.; Macêdo, D. S. Effects of Doxycycline on Depressive-like Behavior in Mice after Lipopolysaccharide (LPS) Administration. J. Psychiatr. Res. 2013, 47 (10), 1521–1529. https://doi.org/10.1016/j.jpsychires.2013.06.008.
(72) Siopi, E.; Chevalier, G.; Katsimpardi, L.; Saha, S.; Bigot, M.; Moigneu, C.; Eberl, G.; Lledo, P.-M. Changes in Gut Microbiota by Chronic Stress Impair the Efficacy of Fluoxetine. Cell Rep. 2020, 30 (11), 3682-3690.e6. https://doi.org/10.1016/j.celrep.2020.02.099.
(73) Sanger, G. J. 5-Hydroxytryptamine and the Gastrointestinal Tract: Where Next? Trends Pharmacol. Sci. 2008, 29 (9), 465–471. https://doi.org/10.1016/j.tips.2008.06.008.
(74) Gershon, M. D. 5-Hydroxytryptamine (Serotonin) in the Gastrointestinal Tract. Curr. Opin. Endocrinol. Diabetes Obes. 2013, 20 (1), 14–21. https://doi.org/10.1097/MED.0b013e32835bc703.
(75) Fiorica-Howells, E.; Maroteaux, L.; Gershon, M. D. Serotonin and the 5-HT(2B) Receptor in the Development of Enteric Neurons. J. Neurosci. Off. J. Soc. Neurosci. 2000, 20 (1), 294–305.
(76) Li, Z.; Chalazonitis, A.; Huang, Y.-Y.; Mann, J. J.; Margolis, K. G.; Yang, Q. M.; Kim, D. O.; Côté, F.; Mallet, J.; Gershon, M. D. Essential Roles of Enteric Neuronal Serotonin in Gastrointestinal Motility and the Development/Survival of Enteric Dopaminergic Neurons. J. Neurosci. Off. J. Soc. Neurosci. 2011, 31 (24), 8998–9009. https://doi.org/10.1523/JNEUROSCI.6684-10.2011.
(77) Lesurtel, M.; Graf, R.; Aleil, B.; Walther, D. J.; Tian, Y.; Jochum, W.; Gachet, C.; Bader, M.; Clavien, P.-A. Platelet-Derived Serotonin Mediates Liver Regeneration. Science 2006, 312 (5770), 104–107. https://doi.org/10.1126/science.1123842.
(78) Murata, S.; Ohkohchi, N.; Matsuo, R.; Ikeda, O.; Myronovych, A.; Hoshi, R. Platelets Promote Liver Regeneration in Early Period after Hepatectomy in Mice. World J. Surg. 2007, 31 (4), 808–816. https://doi.org/10.1007/s00268-006-0772-3.
(79) Bischoff, S. C.; Mailer, R.; Pabst, O.; Weier, G.; Sedlik, W.; Li, Z.; Chen, J. J.; Murphy, D. L.; Gershon, M. D. Role of Serotonin in Intestinal Inflammation: Knockout of Serotonin Reuptake Transporter Exacerbates 2,4,6-Trinitrobenzene Sulfonic Acid Colitis in Mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296 (3), G685-695. https://doi.org/10.1152/ajpgi.90685.2008.
(80) Yadav, V. K.; Ryu, J.-H.; Suda, N.; Tanaka, K. F.; Gingrich, J. A.; Schütz, G.; Glorieux, F. H.; Chiang, C. Y.; Zajac, J. D.; Insogna, K. L.; Mann, J. J.; Hen, R.; Ducy, P.; Karsenty, G. Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Cell 2008, 135 (5), 825–837. https://doi.org/10.1016/j.cell.2008.09.059.
(81) Ghia, J.-E.; Li, N.; Wang, H.; Collins, M.; Deng, Y.; El-Sharkawy, R. T.; Côté, F.; Mallet, J.; Khan, W. I. Serotonin Has a Key Role in Pathogenesis of Experimental Colitis. Gastroenterology 2009, 137 (5), 1649–1660. https://doi.org/10.1053/j.gastro.2009.08.041.
(82) Li, N.; Ghia, J.-E.; Wang, H.; McClemens, J.; Cote, F.; Suehiro, Y.; Mallet, J.; Khan, W. I. Serotonin Activates Dendritic Cell Function in the Context of Gut Inflammation. Am. J. Pathol. 2011, 178 (2), 662–671. https://doi.org/10.1016/j.ajpath.2010.10.028.
(83) Richard, D. M.; Dawes, M. A.; Mathias, C. W.; Acheson, A.; Hill-Kapturczak, N.; Dougherty, D. M. L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications. Int. J. Tryptophan Res. IJTR 2009, 2, 45–60.
(84) Badawy, A. A.; Morgan, C. J.; Lovett, J. W.; Bradley, D. M.; Thomas, R. Decrease in Circulating Tryptophan Availability to the Brain after Acute Ethanol Consumption by Normal Volunteers: Implications for Alcohol-Induced Aggressive Behaviour and Depression. Pharmacopsychiatry 1995, 28 Suppl 2, 93–97. https://doi.org/10.1055/s-2007-979626.
(85) Dougherty, D. M.; Marsh, D. M.; Mathias, C. W.; Dawes, M. A.; Bradley, D. M.; Morgan, C. J.; Badawy, A. A.-B. The Effects of Alcohol on Laboratory-Measured Impulsivity after L: -Tryptophan Depletion or Loading. Psychopharmacology (Berl.) 2007, 193 (1), 137–150. https://doi.org/10.1007/s00213-007-0763-6.
(86) Fukuwatari, T.; Shibata, K. Nutritional Aspect of Tryptophan Metabolism. Int. J. Tryptophan Res. IJTR 2013, 6 (Suppl 1), 3–8. https://doi.org/10.4137/IJTR.S11588.
(87) Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. 3-Hydroxykynurenine, an Endogenous Oxidative Stress Generator, Causes Neuronal Cell Death with Apoptotic Features and Region Selectivity. J. Neurochem. 1998, 70 (1), 299–307. https://doi.org/10.1046/j.1471-4159.1998.70010299.x.
(88) Szabó, N.; Kincses, Z. T.; Toldi, J.; Vécsei, L. Altered Tryptophan Metabolism in Parkinson’s Disease: A Possible Novel Therapeutic Approach. J. Neurol. Sci. 2011, 310 (1–2), 256–260. https://doi.org/10.1016/j.jns.2011.07.021.
(89) Maddison, D. C.; Giorgini, F. The Kynurenine Pathway and Neurodegenerative Disease. Semin. Cell Dev. Biol. 2015, 40, 134–141. https://doi.org/10.1016/j.semcdb.2015.03.002.
(90) Davis, I.; Liu, A. What Is the Tryptophan Kynurenine Pathway and Why Is It Important to Neurotherapeutics? Expert Rev. Neurother. 2015, 15 (7), 719–721. https://doi.org/10.1586/14737175.2015.1049999.
(91) Scientific Opinion on Dietary Reference Values for Niacin. EFSA J. 2014, 12 (7), 3759. https://doi.org/10.2903/j.efsa.2014.3759.
(92) Burhans, M. S.; Dailey, C.; Beard, Z.; Wiesinger, J.; Murray-Kolb, L.; Jones, B. C.; Beard, J. L. Iron Deficiency: Differential Effects on Monoamine Transporters. Nutr. Neurosci. 2005, 8 (1), 31–38. https://doi.org/10.1080/10284150500047070.
(93) Eby, G. A.; Eby, K. L.; Murk, H. Magnesium and Major Depression. In Magnesium in the Central Nervous System; Vink, R., Nechifor, M., Eds.; University of Adelaide Press: Adelaide (AU), 2011.
(94) Ward, M. S.; Lamb, J.; May James, M.; Harrison Fiona, E. Behavioral and Monoamine Changes Following Severe Vitamin C Deficiency. J. Neurochem. 2013, 124 (3), 363–375. https://doi.org/10.1111/jnc.12069.
(95) Styczeń, K.; Sowa-Kućma, M.; Siwek, M.; Dudek, D.; Reczyński, W.; Misztak, P.; Szewczyk, B.; Topór-Mądry, R.; Opoka, W.; Nowak, G. Study of the Serum Copper Levels in Patients with Major Depressive Disorder. Biol. Trace Elem. Res. 2016, 174 (2), 287–293. https://doi.org/10.1007/s12011-016-0720-5.
(96) Kennedy, D. O. B Vitamins and the Brain: Mechanisms, Dose and Efficacy—A Review. Nutrients 2016, 8 (2). https://doi.org/10.3390/nu8020068.
(97) Styczeń, K.; Sowa-Kućma, M.; Siwek, M.; Dudek, D.; Reczyński, W.; Szewczyk, B.; Misztak, P.; Topór-Mądry, R.; Opoka, W.; Nowak, G. The Serum Zinc Concentration as a Potential Biological Marker in Patients with Major Depressive Disorder. Metab. Brain Dis. 2017, 32 (1), 97–103. https://doi.org/10.1007/s11011-016-9888-9.
(98) Schwalfenberg, G. K.; Genuis, S. J. The Importance of Magnesium in Clinical Healthcare. Scientifica 2017, 2017. https://doi.org/10.1155/2017/4179326.
(99) Lee, H.-S.; Chao, H.-H.; Huang, W.-T.; Chen, S. C.-C.; Yang, H.-Y. Psychiatric Disorders Risk in Patients with Iron Deficiency Anemia and Association with Iron Supplementation Medications: A Nationwide Database Analysis. BMC Psychiatry 2020, 20 (1), 216. https://doi.org/10.1186/s12888-020-02621-0.
(100) Shaw, D. M.; Johnson, A. L.; MacSweeney, D. A. Tricyclic Antidepressants and Tryptophan in Unipolar Affective Disorder. Lancet Lond. Engl. 1972, 2 (7789), 1245. https://doi.org/10.1016/s0140-6736(72)92289-1.
(101) Walinder, J.; Skott, A.; Carlsson, A.; Nagy, A.; Bjorn-Erik, R. Potentiation of the Antidepressant Action of Clomipramine by Tryptophan. Arch. Gen. Psychiatry 1976, 33 (11), 1384–1389. https://doi.org/10.1001/archpsyc.1976.01770110112012.
(102) Thomson, J.; Rankin, H.; Ashcroft, G. W.; Yates, C. M.; McQueen, J. K.; Cummings, S. W. The Treatment of Depression in General Practice: A Comparison of L-Tryptophan, Amitriptyline, and a Combination of L-Tryptophan and Amitriptyline with Placebo. Psychol. Med. 1982, 12 (4), 741–751. https://doi.org/10.1017/s0033291700049047.
(103) Avis de l’Agence française de sécurité sanitaire des aliments relatif à l’emploi de tryptophane à hauteur de 1000 mg dans les compléments alimentaires | Anses – Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail https://www.anses.fr/fr/content/avis-de-l%E2%80%99agence-fran%C3%A7aise-de-s%C3%A9curit%C3%A9-sanitaire-des-aliments-relatif-%C3%A0-lemploi-de-2 (accessed May 23, 2020).
(104) Young, S. N. Behavioral Effects of Dietary Neurotransmitter Precursors: Basic and Clinical Aspects. Neurosci. Biobehav. Rev. 1996, 20 (2), 313–323. https://doi.org/10.1016/0149-7634(95)00022-4.
(105) Coppen, A.; Shaw, D. M.; Farrell, J. P. Potentiation of the Antidepressive Effect of a Monoamine-Oxidase Inhibitor by Tryptophan. Lancet Lond. Engl. 1963, 1 (7272), 79–81. https://doi.org/10.1016/s0140-6736(63)91084-5.
(106) Delgado, P. L.; Charney, D. S.; Price, L. H.; Aghajanian, G. K.; Landis, H.; Heninger, G. R. Serotonin Function and the Mechanism of Antidepressant Action. Reversal of Antidepressant-Induced Remission by Rapid Depletion of Plasma Tryptophan. Arch. Gen. Psychiatry 1990, 47 (5), 411–418. https://doi.org/10.1001/archpsyc.1990.01810170011002.
(107) Lam, R. W.; Levitan, R. D.; Tam, E. M.; Yatham, L. N.; Lamoureux, S.; Zis, A. P. L-Tryptophan Augmentation of Light Therapy in Patients with Seasonal Affective Disorder. Can. J. Psychiatry Rev. Can. Psychiatr. 1997, 42 (3), 303–306. https://doi.org/10.1177/070674379704200309.
(108) Steinberg, S.; Annable, L.; Young, S. N.; Liyanage, N. A Placebo-Controlled Clinical Trial of L-Tryptophan in Premenstrual Dysphoria. Biol. Psychiatry 1999, 45 (3), 313–320. https://doi.org/10.1016/s0006-3223(98)00005-5.
(109) Hartmann, E.; Spinweber, C. L. Sleep Induced by L-Tryptophan. Effect of Dosages within the Normal Dietary Intake. J. Nerv. Ment. Dis. 1979, 167 (8), 497–499.